Table 2.
Percentage decrease in viability assessed by Alamar Blue assay of adMSCs and bmMSCs treated with GNOs, GONRs and GONPs at concentration of 300 μg/ml at day 1 and 3 compared to control.
|
|
||||
|---|---|---|---|---|
| adMSC | bmMSC | |||
|
|
||||
| Day 1 | Day 3 | Day 1 | Day 3 | |
| GNOs | 86% | 69% | 50% | 39% |
| GONRs | 93% | 79% | 67% | 72% |
| GONPs | 100% | 98% | 62% | 93% |